Patents by Inventor Steffen Walter

Steffen Walter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC
    Publication number: 20190177368
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Application
    Filed: February 22, 2019
    Publication date: June 13, 2019
    Inventors: Toni WEINSCHENK, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC
    Publication number: 20190177369
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Application
    Filed: February 22, 2019
    Publication date: June 13, 2019
    Inventors: Toni WEINSCHENK, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • Immunotherapy against several tumors, such as lung cancer, including NSCLC
    Patent number: 10316062
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: June 11, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • Immunotherapy against several tumors, such as lung cancer, including NSCLC
    Patent number: 10316063
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: June 11, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC
    Publication number: 20190169233
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Application
    Filed: February 13, 2019
    Publication date: June 6, 2019
    Inventors: Toni WEINSCHENK, Steffen WALTER, Jens FRITSCHE, Colette SONG, Harpreet SINGH
  • PRE-TREATMENT, METHOD FOR ADDITIVE PRODUCTION OF A COMPONENT, AND DEVICE
    Publication number: 20190105709
    Abstract: A method for additive production and a correspondingly produced component made of a powdery base material, includes the thermal pre-treatment of the base material at a first temperature of at least 800° C. under an inert gas atmosphere, wherein the first temperature and a duration of the pre-treatment are further selected such that no sintering process of the base material occurs, subsequent cooling of the base material, and additive construction of the component from the thermally pre-treated base material. A corresponding device is for the additive production.
    Type: Application
    Filed: May 8, 2017
    Publication date: April 11, 2019
    Applicant: Siemens Aktiengesellschaft
    Inventors: Christian Brunhuber, Axel Papperitz, Steffen Walter
  • NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS
    Publication number: 20190076477
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 14, 2019
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
  • NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS
    Publication number: 20190076476
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 14, 2019
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
  • Immunotherapy against several tumors including neuronal and brain tumors
    Patent number: 10227381
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: March 12, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
  • METHOD FOR PRODUCING A WORK PIECE THROUGH GENERATIVE MANUFACTURING, AND CORRESPONDING WORK PIECE
    Publication number: 20190061057
    Abstract: A method for producing a work piece includes the providing of a substrate having a predetermined surface structure and the generative manufacturing of a material for the work piece on the surface structure, such that the surface structure defines a base surface of the work piece to be manufactured, wherein the generative manufacturing is carried out by deposition welding and wherein the base surface is an at least partially interior surface of the work piece in respect of a contour of the work piece that is to be manufactured. The method furthermore includes the detaching of the substrate.
    Type: Application
    Filed: September 27, 2016
    Publication date: February 28, 2019
    Applicant: Siemens Aktiengesellschaft
    Inventors: Christian Brunhuber, Stefan Denneler, Moritz Fischle, Henning Hanebuth, Steffen Walter
  • NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS
    Publication number: 20190010190
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: September 19, 2018
    Publication date: January 10, 2019
    Inventors: Toni WEINSCHENK, Oliver SCHOOR, Claudia TRAUTWEIN, Norbert HILF, Steffen WALTER, Harpreet SINGH
  • IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC
    Publication number: 20190002504
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Application
    Filed: August 10, 2018
    Publication date: January 3, 2019
    Inventors: Toni WEINSCHENK, Steffen WALTER, Jens FRITSCHE, Colette SONG, Harpreet SINGH
  • Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
    Patent number: 10159725
    Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gastric cancers (GC).
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: December 25, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Immunotherapy against several tumors, such as lung cancer, including NSCLC
    Patent number: 10160786
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: December 25, 2018
    Assignee: Immatics Biotechnologies GMBH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
    Publication number: 20180319884
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: July 13, 2018
    Publication date: November 8, 2018
    Inventors: Leonie ALTEN, Dominik MAURER, Steffen WALTER, Sebastian BUNK
  • Immunotherapy against several tumors including neuronal and brain tumors
    Patent number: 10100085
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: October 16, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
  • Immunotherapy against several tumors, such as lung cancer, including NSCLC
    Patent number: 10071148
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to more than 70 novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: September 11, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • Immunotherapy against several tumors including gastrointestinal and gastric cancer
    Patent number: 10064913
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: September 4, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Jens Fritsche, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Immunotherapy against several tumors including neuronal and brain tumors
    Patent number: 10046037
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: August 14, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
  • Immunotherapy against several tumors including neuronal and brain tumors
    Patent number: 10047123
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: August 14, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh